SURVYR

CGON

CG Oncology, Inc.
$63.96
+$1.02 (1.62%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-19%+6%+32%+57%+83%Oct 2025Oct 2026Apr 202652w high $80.9752w low $35.80
CGONSPY
Wall St. Highest PT $108.00 (+68.9%) Wall St. Avg PT $91.08 (+42.4%)
$37$56$75$94$113POC $70Hi $108Avg $91
Underwater Drawdown %Max DD -27.4%Current -20.7%
0.0%-27.4%
Relative Strength vs SPY+30.5% vs SPYOutperforming
+79%0%-79%
1W
+$1.72 (2.76%)
1M
−$5.65 (8.12%)
3M
−$5.16 (7.47%)
6M
−$0.79 (1.22%)
YTD
+$22.44 (54.05%)
1Y
+$20.25 (46.33%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
15 analysts · mean score 1.40
1 = Strong Buy · 5 = Sell
Strong Buy1067%
Buy427%
Hold17%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 21, 2026
Analyst price targets
Current price$63.96
Average target$91.08
+$27.12 (+42.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$79.00
Median$90.00
High$108.00
12-month Wall Street target range · as of Oct 21, 2026
Recent analyst rating changes · 30
Reiterated
2026-08-07 · RBC Capital reiterated Outperform on CGON
Reiterated
2026-08-07 · Piper Sandler reiterated Overweight on CGON
Reiterated
2026-08-07 · Truist Securities reiterated Buy on CGON
Initiated
2026-05-19 · Wolfe Research started covering CGON at Peer Perform
Reiterated
2026-05-18 · HC Wainwright & Co. reiterated Buy on CGON
Reiterated
2026-05-14 · Truist Securities reiterated Buy on CGON
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Safe zone
Altman Z-score 57.7
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Weak
Piotroski F-score 2 of 9
See the tests
  • ✗Positive net income
  • ✗Positive operating cash flow
  • ✗Return on assets improved
  • ✓Cash flow above net income
  • ✗Long-term debt / assets fell
  • ✗Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$5.5B
P/E (next 12 months, estimated)-20.4
52-week range$35.80 – $80.97
Dividend yieldNo dividend
Analyst consensusStrong Buy (13)
Average analyst price target$91.08 (+42%)

What they do

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▼Piotroski F-score2/9
▲Altman Z57.7 (safe)
▲Analyst target+42% (13 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.28 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-3.02 vs trailing $-2.69. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
-4056.2%
FCF margin
-2879.6%
Net margin
-3602.7%
Return on equity
-21.8%
Return on invested capital
-5197.1%
Net debt / EBITDA
–
Current ratio
22.2×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 2/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 57.7 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$91
+42%
Analysts
13
Strong Buy
Range
$79–$108
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$4.0M$-161.0M$-132.5M
2024$1.1M$-88.0M$-78.9M
2023$204.0K$-48.6M$-45.7M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

For information only · Important disclosures

Grades vs sector

No sector grades for CGON yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Biotech, -12% from 52-week high, biotech, price-only entry, 12-1 momentum +92%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-28) it is outside the top 25.

Earnings & events

CGON earningsNext report in 12 days
Next report
Mon Nov 9, 2026Before the open
EPS consensus-$0.81 range -$0.96–-$0.66
Revenue consensus$534.5K 12 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.90est -$0.64−40.1%Below estimates
May 8, 2026-$0.71est -$0.54−31.5%Below estimates
Feb 27, 2026-$0.51est -$0.58+12.6%Above estimates
Nov 14, 2025-$0.57est -$0.55−4.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 12:19:46 ET
24-1125-0325-0525-0825-1126-0226-0526-08-0.900.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.2M–
2026-03-31$1.1M–
2025-12-31$2.3M–
2025-09-30$1.7M–
2025-06-30$0–

News & catalysts

More news
How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch
Simply Wall St. · Oct 13
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
GlobeNewswire · Oct 13
3 Stocks Call Traders Are Targeting Today
Schaeffer's Investment Research · Sep 11
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
Simply Wall St. · Sep 03
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
PR Newswire · Aug 26
Rating changes
Reiterated
2026-08-07 · RBC Capital reiterated Outperform on CGON
Reiterated
2026-08-07 · Piper Sandler reiterated Overweight on CGON
Reiterated
2026-08-07 · Truist Securities reiterated Buy on CGON
Initiated
2026-05-19 · Wolfe Research started covering CGON at Peer Perform
Reiterated
2026-05-18 · HC Wainwright & Co. reiterated Buy on CGON
Reiterated
2026-05-14 · Truist Securities reiterated Buy on CGON

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Post Leonard E
Director · 2026-10-15
Sell
$31.2K
Post Leonard E
Director · 2026-10-15
Sell
$30.8K
Post Leonard E
Director · 2026-09-15
Sell
$73.0K
Post Leonard E
Director · 2026-08-14
Sell
$74.5K
None
None · None
Sell
–

Stats refreshed 2026-10-24 12:19:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026